A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Inclusion Criteria:

- Age >=18 years

- For paclitaxel combination arms: histologically or cytologically documented
adenocarcinoma of the breast with locally recurrent or metastatic disease

- For docetaxel combination arms: histologically or cytologically documented
adenocarcinoma of the breast with locally recurrent or metastatic disease or
histologically documented advanced (Stage IV) or recurrent NSCLC

- For participants with breast cancer: HER2-negative disease as defined by local
clinical guidelines

- Participants with NSCLC to be treated with docetaxel need to have received at least
one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel
be considered appropriate treatment

- Evaluable or measurable disease per response evaluation criteria in solid tumors
(RECIST) v.1.1

- Life expectancy >=12 weeks

- Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening

- Adequate hematologic and end organ function

- Use of highly effective form of contraception

Exclusion Criteria:

- Prior anti-cancer therapy

- Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor

- Known significant hypersensitivity to any components of study treatment

- Grade >=2 peripheral neuropathy

- Type 1 or Type 2 diabetes

- Grade >=2 hypercholesterolemia or hypertriglyceridemia

- Congenital long QT syndrome

- Active congestive heart failure or ventricular arrhythmia